TITLE:
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

CONDITION:
Sarcoma, Kaposi

INTERVENTION:
Mitoxantrone hydrochloride

SUMMARY:

      To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in
      AIDS-related Kaposi's sarcoma.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have the following:

          -  Biopsy proven Kaposi's sarcoma in advanced stages.

          -  Positive HIV antibody, HIV culture or antigen capture or T4 cells < 500 in a patient
             with AIDS risk factor.

          -  Informed consent and availability for follow-up.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Uncontrolled opportunistic infection.

          -  Any medical, surgical or psychiatric condition which would constitute a
             contraindication to the use of mitoxantrone.

        Concurrent Medication:

        Excluded:

          -  Zidovudine (AZT).

        Patients with the following are excluded:

          -  Uncontrolled opportunistic infection.

          -  Unable to give informed consent.

          -  Any medical, surgical or psychiatric condition which would constitute a
             contraindication to the use of mitoxantrone.

        Prior Medication:

        Excluded:

          -  More than one form of chemotherapy regimen.

          -  Doxorubicin therapy > 300 mg/m2.

        Prior Treatment:

        Excluded:

          -  Previous therapy consisting of more than one modality of therapy (e.g., chemotherapy
             plus radiotherapy or more than one form of chemotherapy regimen.)
      
